Save this technology
Save to Existing Project
Save to a New Project
Targeting CD36 in the Treatment of Dry Age-related Macular Degeneration (dry AMD) and Its Late Form (geographic Atrophy)
AmorChem Canada flag Canada
Abstract ID:
CD36 ligands were found to diminish sub-retinal deposits in apoE-null mice, known to accumulate lipids and other remnants and to reduce macrophage accumulation in the vasculature (analogous to what occurs in AMD)....
Contact John Clement
Email me a copy of this message

Age-related macular degeneration (AMD) is one of the leading causes of blindness in industrialized countries. There are two clinical forms of AMD: a ‘dry' form (termed geographic atrophy). To date, there are only effective therapeutic interventions for ‘wet AMD'.

CD36, a multiligand receptor, is expressed on retinal pigment epithelium (RPE), microvascular endothelium cell (EC), and to a greater extent on macrophages. CD36 is involved in various functions:

(1) Cellular energy uptake by acting as a long chain fatty acid receptor;

(2) Uptake of oxidized lipoproteins;

(3) Phagocytosis of retinal outer segment - essential to recycle spent photoreceptor disks;

(4) In modulating inflammatory response and oxidative stress and;

(5) In angiogenesis.

Collectively, the properties of CD36 are aligned with factors implicated in the genesis of dry AMD, and correspondingly the negative modulatory effect of CD36 should postpone the progression of the disease.

Type of Business Relationship Sought
Out-licensing or collaboration
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL

Opportunity Contact